New Triple-Threat vaccine trial aims to shield seniors from winter viruses
NCT ID NCT06984094
First seen May 13, 2026 · Last updated May 22, 2026 · Updated 4 times
Summary
This study tests two new vaccines (SCB-1022 and SCB-1033) in healthy adults aged 60-85. The vaccines target three respiratory viruses: RSV, human metapneumovirus, and parainfluenza. The goal is to see if they are safe and boost the immune system. About 612 participants will be involved.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RSV INFECTION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Fusion Clinical Research
Adelaide, Southern Australia, 5067, Australia
-
Linear Clinical Research
Perth, Western Australia, 6009, Australia
-
Paratus Clinical Research
Melbourne, Victoria, 3070, Australia
Conditions
Explore the condition pages connected to this study.